{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015768","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.700795+00:00","generated_at":"2026-06-24T02:08:21.533178+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PMV Pharma Q2 net loss $35.7M; cash $277.4M; PC14586 combo with KEYTRUDA planned","bullets":["Net loss for H1 2022: $35.7M vs $24.5M YoY; cash, cash equivalents and marketable securities $277.4M as of June 30, 2022.","R&D expenses $23.3M in H1 2022 vs $15.2M in H1 2021, driven by PC14586 clinical trial costs.","Initial PC14586 Phase 1 data presented at ASCO; entered clinical collaboration with Merck for PC14586 + KEYTRUDA combo trial starting Q4 2022.","Appointed Marc Fellous, M.D. as VP, Clinical Development and Medical Affairs; previous experience at Bayer and Roche.","Net cash used in operations $31.7M in H1 2022 vs $22.1M in H1 2021; cash burn increased 43%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015768","json":"https://secwatch.observer/filing/0000950170-22-015768.json","markdown":"https://secwatch.observer/filing/0000950170-22-015768.md","text":"https://secwatch.observer/filing/0000950170-22-015768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017022015768/0000950170-22-015768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017022015768/pmvp-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:08:21.533178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}